FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 59 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Banking on breakthroughs for children and young people September 27, 2022 Lighting Ceremony at Lincoln Memorial Honors the 400,000 Lives Lost to... January 20, 2021 FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... September 12, 2024 Speaking with One Cancer Voice for cancer patients in England March 29, 2023 Load more HOT NEWS Lisocabtagene Maraleucel in Relapsed or Refractory Large B-cell Lymphomas MAP Congress 2020: Molecular Analysis for Precision Oncology Young Mom Battles Breast Cancer After Being Misdiagnosed with a Blocked... The Unique Challenges Teenagers and Young Adults With Cancer Face: An...